A clinical trial to determine clinical outcomes in unresectable HCC patients who underwent treatment with atezolizumab and bevacizumab
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
Most Recent Events
- 14 Jun 2024 New trial record
- 10 Apr 2024 According to Results presented at the 115th Annual Meeting of the American Association for Cancer Research, the number of patients are small in this trial and accrual is still ongoing,